Abstract:White adipose tissue undergoes dynamic changes in obesity, including adipose tissue pathological expansion, hypoxia, adipose tissue fibrosis, immune cells infiltration and finally leads to chronic low‐grade inflammation and insulin resistance. White adipose tissue is not only a highly heterogeneous organ containing various cells, such as adipocytes, adipose stem and progenitor cells, and immune cells, but also an endocrine organ that is highly important for regulating metabolic and immune homeostasis. In individuals with obesity, dynamic cellular changes in adipose tissue result in phenotypic switching and adipose tissue dysfunction, including pathological expansion, WAT fibrosis, immune cell infiltration, endoplasmic reticulum stress, and ectopic lipid accumulation, ultimately leading to chronic low‐grade inflammation and insulin resistance. Recently, many distinct subpopulations of adipose tissue have been identified, providing new insights into the potential mechanisms of adipose dysfunction in individuals with obesity. Therefore, targeting white adipose tissue as a therapeutic agent for treating obesity and obesity‐related metabolic diseases is of great scientific interest. Here, we provide an overview of white adipose tissue remodeling in individuals with obesity including cellular changes and discuss the underlying regulatory mechanisms of white adipose tissue metabolic dysfunction. Currently, various studies have uncovered promising targets and strategies for obesity treatment. We also outline the potential therapeutic signaling pathways of targeting adipose tissue and summarize existing therapeutic strategies for antiobesity treatment including pharmacological approaches, lifestyle interventions, and novel therapies.

Correction To: Signaling pathways in obesity: mechanisms and therapeutic interventions

Correction to: Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells

Correction: The Hippo signalling pathway and its implications in human health and diseases

Author correction to ‘Ablation of Akt2 and AMPKα2 rescues high fat diet-induced obesity and hepatic steatosis through Parkin-mediated mitophagy’ [Acta Pharmaceutica Sinica B 11 (2021) 3508–3526]

Erratum. Obese Skeletal Muscle–Expressed Interferon Regulatory Factor 4 Transcriptionally Regulates Mitochondrial Branched-Chain Aminotransferase Reprogramming Metabolome. Diabetes 2022;71:2256–2271

Corrigendum to “Lipopolysaccharide-Induced Podocyte Injury is Regulated by Calcineurin/nfat and TLR4/MyD88/NF-κB Signaling Pathways Through Angiopoietin-like Protein 4” [genes & Diseases 9(2022) 443–455]

Author Correction: A new era in obesity management

Shared signaling pathways and targeted therapy by natural bioactive compounds for obesity and type 2 diabetes

Author Correction: Targeted Pharmacological Therapy Restores Β-Cell Function for Diabetes Remission

Corrigendum to “Modulation of Short-Chain Fatty Acids as Potential Therapy Method for Type 2 Diabetes Mellitus”

Author Correction: Targeted inhibition of ubiquitin signaling reverses metabolic reprogramming and suppresses glioblastoma growth

Correction to: Hyperglycemia promotes myocardial dysfunction via the ERS-MAPK10 signaling pathway in db/db mice

Correction: The JAK-STAT pathway: from structural biology to cytokine engineering

Corrigendum: Blood Immune Cell Composition Associated With Obesity and Drug Repositioning Revealed by Epigenetic and Transcriptomic Conjoint Analysis

Therapeutic targeting of white adipose tissue metabolic dysfunction in obesity: mechanisms and opportunities

Correction to: The Protective Effects of Butorphanol on Pulmonary Function of Patients with Obesity Undergoing Laparoscopic Bariatric Surgery: A Double-Blind Randomized Controlled Trial

Correction: Characterization of a small-molecule inhibitor targeting NEMO/IKKβ to suppress colorectal cancer growth

Correction: Fan et al. Progress in the Preclinical and Clinical Study of Resveratrol for Vascular Metabolic Disease. Molecules 2022, 27, 7524

Correction: Transcription factors in colorectal cancer: molecular mechanism and therapeutic implications

Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

Correction to: NUPR1 promotes the proliferation and metastasis of oral squamous cell carcinoma cells by activating TFE3-dependent autophagy